Clinical Trial Update: Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating minimal residual disease–driven deferral of transplant in dysproteinemia, including multiple myeloma and AL amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Multiple Myeloma, Amyloidosis | Phase 2 | Status: RECRUITING